BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SYH2053 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SYH2053\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07938034-1056@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:SYH2053: Phase 1 readout est. (NCT07938034)
DESCRIPTION:SYH2053\, phase 1.\nStudy: A Study of SYH2053 Injection in Part
 icipants With Renal Impairment Compared to Participants With Normal Renal 
 Function\nEstimated primary completion: 15 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/syh2053#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07938034
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421284-1056@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421284)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 in Chinese Parti
 cipants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on
  a Background of Lipid-lowering Therapy\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 421284
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421297-1056@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421297)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 as Monotherapy i
 n Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyp
 erlipidemia\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/syh2053#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07421297
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465263-1056@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SYH2053: Phase 3 readout est. (NCT07465263)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygo
 us Familial Hypercholesterolemia (HeFH)\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 465263
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
